GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Cash Ratio

Athira Pharma (Athira Pharma) Cash Ratio : 5.11 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Athira Pharma's Cash Ratio for the quarter that ended in Dec. 2023 was 5.11.

Athira Pharma has a Cash Ratio of 5.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Athira Pharma's Cash Ratio or its related term are showing as below:

ATHA' s Cash Ratio Range Over the Past 10 Years
Min: 1.62   Med: 8.89   Max: 41.93
Current: 5.11

During the past 6 years, Athira Pharma's highest Cash Ratio was 41.93. The lowest was 1.62. And the median was 8.89.

ATHA's Cash Ratio is ranked better than
66.36% of 1525 companies
in the Biotechnology industry
Industry Median: 2.9 vs ATHA: 5.11

Athira Pharma Cash Ratio Historical Data

The historical data trend for Athira Pharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma Cash Ratio Chart

Athira Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 1.62 41.93 27.31 9.35 5.11

Athira Pharma Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.35 9.23 8.59 6.04 5.11

Competitive Comparison of Athira Pharma's Cash Ratio

For the Biotechnology subindustry, Athira Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athira Pharma's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athira Pharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Athira Pharma's Cash Ratio falls into.



Athira Pharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Athira Pharma's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=147.419/28.84
=5.11

Athira Pharma's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=147.419/28.84
=5.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athira Pharma  (NAS:ATHA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Athira Pharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Athira Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athira Pharma (Athira Pharma) Business Description

Traded in Other Exchanges
N/A
Address
18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Executives
Mark James Litton officer: Chief Operating Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington officer: General Counsel C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Rachel Lenington officer: Chief Technology Officer C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrew Gengos officer: See Below 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Grant Pickering director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Kevin Church officer: Vice President of Discovery 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Glenna Mileson officer: Chief Financial Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Kelly A Romano director C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Hans Moebius officer: Chief Medical Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara director 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014

Athira Pharma (Athira Pharma) Headlines

From GuruFocus

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

By Stock market mentor Stock market mentor 01-31-2023